Mood Disorders

Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to Selective Serotonin Reuptake Inhibitors: The VIVRE Study

This study assessed the efficacy of vortioxetine versus desvenlafaxine in patients with MDD experiencing partial response to treatment with an SSRI. Vortioxetine was noninferior to desven...

Michael C. Fischi , MD;

10/26/2023

Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar II Disorder

This post hoc, pooled analysis of 3 short-term, placebo-controlled studies evaluated the efficacy of once-daily lumateperone 42mg monotherapy and adjunctive therapy in patients experienci...

William Rowe , MSN, RN, ACNP, BC;

10/26/2023

Equivalent Antidepressant Outcomes with Esketamine in TMS Non-Responders

Both Transcranial Magnetic Stimulation (TMS) and Esketamine are FDA approved therapies for patients with Major Depressive Disorder who have failed at least one conventional antidepressant...

Tobias F. Marton , MD, PhD;

10/26/2023

Esketamine Nasal Spray Improves Functioning in Patients with Treatment Resistant Depression: Results from ESCAPE‑TRD

This analysis evaluated changes in functioning and productivity in patients with treatment resistant depression who received either esketamine nasal spray or quetiapine extended release, ...

Hannah Bowrey , PhD;

10/26/2023

EEG Individual Alpha Frequencies May Improve Depression Symptoms in TMS Treatment

69 patients were grouped based on their baseline individual alpha frequency (IAF): 8, 9, 10, or 11 Hz. We show the percentage of patients in each group that reported a decrease, increase,...

10/26/2023

Effect of Adjunctive Cariprazine on Symptoms of Anhedonia in Patients with Major Depressive Disorder

Results from this post-hoc analysis suggest adjunctive cariprazine treatment may be effective for improving symptoms of anhedonia in patients with major depressive disorder.

Majid Kerolous , PharmD, MPH;

10/26/2023

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder and Early-Stage Dementia: The MEMORY Study

The MEMORY study demonstrates the effectiveness of vortioxetine in clinically significantly improving depressive symptoms, cognitive performance, daily functioning, and HRQoL, as well as ...

Michael C. Fischi , MD;

10/26/2023

Effects of Adjunctive Brexpiprazole on Patient Life Engagement in Major Depressive Disorder Analyzed by Baseline Clinical Characteristics: Post Hoc analysis of a Phase 4, Open-Label Study

This post hoc analysis of a Phase 4, open-label, 8-week study evaluated if baseline clinical characteristics may influence the effect of adjunctive brexpiprazole on patient life engagemen...

Francois Therrien , PharmD;

10/26/2023

Cariprazine as an Adjunctive Treatment for Major Depressive Disorder: Assessment of Benefit and Risk Using Number Needed to Treat and Number Needed to Harm

The benefit-risk profile of cariprazine is favorable for major depressive disorder adjunctive treatment.

Majid Kerolous , PharmD, MPH;

10/26/2023

Changes in Metabolic Parameters Associated With Lumateperone in Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis of 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-controlled adjunctive study evalua...

Jayanth R. Arnold , MD;

10/26/2023